ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

CKD-846

A development code.

Its studies are mostly in Prostatic Hyperplasia, led by Chong Kun Dang Pharmaceutical.

Furthest: phase 1, since Oct 19, 20232 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chong Kun Dang Pharmaceutical20 open or runningphase 1since Oct 19, 2023Oct 19, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 19, 2023First study: phase 1 study in Prostatic HyperplasiaFirst studyNCT06110923 · 31 enrolled · South Korea
  2. Jan 29, 2026Phase 1 study in Prostatic HyperplasiaNCT07404735 · 34 enrolled · South Korea

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07404735Prostatic Hyperplasia · South Korea1CompletedJun 2, 202634
NCT06110923Prostatic Hyperplasia · South Korea1CompletedMay 10, 202431

How it is read

Names in the registry

  • “CKD-846”, 2 entries

Codes read as this program: CKD846.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.